


PHARMACEUTICAL 2019

NeuroBo Pharmaceuticals Inc. Rank 305 of 371





PHARMACEUTICAL 2019

NeuroBo Pharmaceuticals Inc. Rank 305 of 371

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 280% points.

The company's Economic Capital Ratio, given in the ranking table, is -553%, being 222% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	19,686
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,919
Liabilities, Non-Current	1.0
Other Assets	8.0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-832
Property and Equipment	0
Research and Development	14,312
Revenues	0
Selling, General and Administrative Expense	8,493

Output Variable	Value in 1000 USD
Assets	19,694
Liabilities	11,920
Expenses	22,805
Stockholders Equity	7,774
Net Income	-23,637
Comprehensive Net Income	-23,637
Economic Capital Ratio	-553%